Yi Lin

39.9k citations

307 papers · 9.3k · 4 hit papers · h-index 45

Impact in

Oncology top 0.2%
- CAR-T cell therapy research
Hematology top 0.5%
- Multiple Myeloma Research and Treatments

Papers in

Oncology 156
- CAR-T cell therapy research 132
- Cancer Immunotherapy and Biomarkers 15
Molecular Biology 67
- Amyloidosis: Diagnosis, Treatment, Outcomes 23
- Protein Degradation and Inhibitors 17

Co-authors: Anna Solovey (3 shared papers)Robert P. Hebbel (3 shared papers)Daniel J. Weisdorf (1 shared paper)Allan B. Dietz (18 shared papers)Sattva S. Neelapu (32 shared papers)Frederick L. Locke (33 shared papers)Michael P. Gustafson (12 shared papers)Peggy A. Bulur (9 shared papers)
Journals: Journal of Clinical Oncology (62 papers)Blood (55 papers)American Journal of Hematology (14 papers)Transplantation and Cellular Therapy (13 papers)Blood Cancer Journal (12 papers)
Partner nations: United States China France

In The Last Decade

Yi Lin

280 papers receiving 9.2k citations

Yi Lin's Hit Papers

align trajectories log scale

Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial 2022 · 198 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2022 Nature Medicine
2017 Nature Reviews Clinical Oncology
2000 Journal of Clinical Investigation
1997 New England Journal of Medicine

Peers

Countries citing papers authored by Yi Lin

Since Specialization

Citations

This map shows the geographic impact of Yi Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yi Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yi Lin more than expected).

Fields of papers citing papers by Yi Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yi Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yi Lin. The network helps show where Yi Lin may publish in the future.

Co-authors

The 25 scholars most cited alongside Yi Lin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Yi Lin Line = papers co-authored together Yi Lin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 307 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Chimeric antigen receptor T-cell therapy — assessment and management of toxicities Nature Reviews Clinical Oncology ·Sattva S. Neelapu, Sudhakar Tummala, Partow Kebriaei, William G. Wierda, Cristina Gutiérrez, Frederick L. Locke, Krishna V. Komanduri, Yi Lin, Nitin Jain, Naval Daver, Jason R. Westin, Alison Gulbis, Monica Loghin, John de Groot, Sherry Adkins, Suzanne E. Davis, Katayoun Rezvani, Patrick Hwu, Elizabeth J. Shpall Hit paper breakdown →	2017	1666
2	Origins of circulating endothelial cells and endothelial outgrowth from blood Journal of Clinical Investigation ·Yi Lin, Daniel J. Weisdorf, Anna Solovey, Robert P. Hebbel Hit paper breakdown →	2000	1190
3	Circulating Activated Endothelial Cells in Sickle Cell Anemia New England Journal of Medicine ·Anna Solovey, Yi Lin, Paul Browne, Stephana Choong, Elizabeth A. Wayner, Robert P. Hebbel Hit paper breakdown →	1997	510
4	Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma Blood Advances ·Frederick L. Locke, John M. Rossi, Sattva S. Neelapu, Caron A. Jacobson, David B. Miklos, Armin Ghobadi, Olalekan O. Oluwole, Patrick M. Reagan, Lazaros J. Lekakis, Yi Lin, Marika Sherman, Marc Better, William Y. Go, Jeffrey S. Wiezorek, Allen Xue, Adrian Bot	2020	282
5	Immunosuppressive CD14⁺HLA‐DR^low/− monocytes in prostate cancer The Prostate ·Stanimir Vuk‐Pavlović, Peggy A. Bulur, Yi Lin, Rui Qin, Carol L. Szumlanski, Xinghua Zhao, Allan B. Dietz	2009	220
6	Immunosuppressive CD14+HLA-DRlow/− monocytes in B-cell non-Hodgkin lymphoma Blood ·Yi Lin, Michael P. Gustafson, Peggy A. Bulur, Dennis A. Gastineau, Thomas E. Witzig, Allan B. Dietz	2010	205
7	Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties Neuro-Oncology ·Jennifer C. Rodrigues, G. C. Gonzalez, Lei Zhang, George M. Ibrahim, John J. Kelly, Michael P. Gustafson, Yi Lin, Allan B. Dietz, Peter Forsyth, V. Wee Yong, Ian F. Parney	2009	201
8	Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial Nature Medicine ·Sattva S. Neelapu, Michael Dickinson, Javier Muñoz, Matthew L. Ulrickson, Catherine Thiéblemont, Olalekan O. Oluwole, Alex F. Herrera, Chaitra S. Ujjani, Yi Lin, Peter A. Riedell, Natasha Kekre, Sven de Vos, Christine Lui, Francesca Milletti, Jinghui Dong, Hairong Xu, Julio C. Chávez Hit paper breakdown →	2022	198
9	Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone Neuro-Oncology ·Michael P. Gustafson, Yi Lin, Kent C. New, Peggy A. Bulur, Brian Patrick O’Neill, Dennis A. Gastineau, Allan B. Dietz	2010	190
10	Mesenchymal Stem Cell Carriers Protect Oncolytic Measles Viruses from Antibody Neutralization in an Orthotopic Ovarian Cancer Therapy Model Clinical Cancer Research ·Emily K. Mader, Yoshihiro Maeyama, Yi Lin, Greg W. Butler, Holly Russell, Evanthia Galanis, Stephen J. Russell, Allan B. Dietz, Kah-Whye Peng	2009	163
11	Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis Journal of Clinical Oncology ·Taxiarchis Kourelis, Shaji Kumar, Morie A. Gertz, Martha Q. Lacy, Francis K. Buadi, Suzanne R. Hayman, Steven R. Zeldenrust, Nelson Leung, Robert A. Kyle, Stephen J. Russell, David Dingli, John A. Lust, Yi Lin, Prashant Kapoor, S. Vincent Rajkumar, Arleigh McCurdy, Angela Dispenzieri	2013	149
12	Use of blood outgrowth endothelial cells for gene therapy for hemophilia A Blood ·Yi Lin, Liming Chang, Anna Solovey, John F. Healey, Pete Lollar, Robert P. Hebbel	2002	133
13	Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma Journal of Clinical Oncology ·Prashant Kapoor, Shaji Kumar, Angela Dispenzieri, Martha Q. Lacy, Francis K. Buadi, David Dingli, Stephen J. Russell, Suzanne R. Hayman, Thomas E. Witzig, John A. Lust, Nelson Leung, Yi Lin, Steven R. Zeldenrust, Arleigh McCurdy, Philip R. Greipp, Robert A. Kyle, S. Vincent Rajkumar, Morie A. Gertz	2013	121
14	Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL' Nature Reviews Clinical Oncology ·Sattva S. Neelapu, Sudhakar Tummala, Partow Kebriaei, William G. Wierda, Frederick L. Locke, Yi Lin, Nitin Jain, Naval Daver, Alison Gulbis, Sherry Adkins, Katayoun Rezvani, Patrick Hwu, Elizabeth J. Shpall	2018	106
15	Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results. Journal of Clinical Oncology ·Nikhil C. Munshi, Larry D. Anderson, Nina Shah, Sundar Jagannath, Jesús G. Berdeja, Sagar Lonial, Noopur Raje, David S. Siegel, Yi Lin, Albert Oriol, Philippe Moreau, Ibrahim Yakoub‐Agha, Michel Delforge, Fabio Petrocca, Jamie N. Connarn, Payal Patel, Liping Huang, Timothy Campbell, Kristen Hege, Jesús F. San Miguel, (unknown)	2020	96
16	Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma Blood Cancer Journal ·Wilson I. Gonsalves, Nelson Leung, S. Vincent Rajkumar, Angela Dispenzieri, Martha Q. Lacy, Suzanne R. Hayman, Francis K. Buadi, David Dingli, Prashant Kapoor, Ronald S. Go, Yi Lin, Stephen J. Russell, John A. Lust, Steven R. Zeldenrust, Robert A. Kyle, Morie A. Gertz, Shaji Kumar	2015	93
17	A Method for Identification and Analysis of Non-Overlapping Myeloid Immunophenotypes in Humans PLoS ONE ·Michael P. Gustafson, Yi Lin, Mary Maas, Virginia P. Van Keulen, Patrick B. Johnston, Tobias Peikert, Dennis A. Gastineau, Allan B. Dietz	2015	89
18	IL-10 induces the development of immunosuppressive CD14+HLA-DRlow/− monocytes in B-cell non-Hodgkin lymphoma Blood Cancer Journal ·B Xiu, Yi Lin, D M Grote, Steven C. Ziesmer, Michael P. Gustafson, (unknown), Z. Zhang, Allan B. Dietz, Luis F. Porrata, Anne J. Novak, A-B Liang, Z-Z Yang, S. Ansell	2015	81
19	CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma. Journal of Clinical Oncology ·Yi Lin, Thomas Martin, (unknown), Jesús G. Berdeja, Andrzej Jakubowiak, Mounzer Agha, Adam D. Cohen, Abhinav Deol, Myo Htut, Alexander M. Lesokhin, Nikhil C. Munshi, Elizabeth O’Donnell, Carolyn C. Jackson, Tzu‐Min Yeh, Arnob Banerjee, Enrique Zudaire, Deepu Madduri, Christopher delCorral, Lida Bubuteishvili‐Pacaud, Sundar Jagannath	2023	77
20	TRPM7 channel inhibition attenuates rheumatoid arthritis articular chondrocyte ferroptosis by suppression of the PKCα-NOX4 axis Redox Biology ·Renpeng Zhou, Yong Chen, Shufang Li, Xin Wei, Weirong Hu, Su’an Tang, Jie Ding, Wanjin Fu, Hailin Zhang, Fan Chen, Wen‐Juan Hao, Yi Lin, Rendi Zhu, Ke Wang, Lei Dong, Yingjie Zhao, Xiaowen Feng, Feihu Chen, Changhai Ding, Wei Hu	2022	77

About Yi Lin

Yi Lin is a scholar working on Oncology, Molecular Biology, Hematology, Immunology and Pathology and Forensic Medicine, having authored 307 papers that have together received 9.3k indexed citations. Recurring topics across this work include CAR-T cell therapy research (132 papers), Multiple Myeloma Research and Treatments (57 papers), Lymphoma Diagnosis and Treatment (33 papers), Biosimilars and Bioanalytical Methods (29 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (23 papers), Chronic Lymphocytic Leukemia Research (21 papers), Protein Degradation and Inhibitors (17 papers) and Cancer Immunotherapy and Biomarkers (15 papers). The work is most often cited by research in Oncology (4.6k citations), Hematology (1.6k citations), Genetics (1.1k citations), Immunology (1.8k citations) and Molecular Biology (3.5k citations). Yi Lin has collaborated with scholars based in United States, China and France. Frequent co-authors include Anna Solovey, Robert P. Hebbel, Daniel J. Weisdorf, Allan B. Dietz, Sattva S. Neelapu, Frederick L. Locke, Michael P. Gustafson, Peggy A. Bulur, William G. Wierda and Sherry Adkins. Their work appears in journals such as Journal of Clinical Oncology, Blood, American Journal of Hematology, Transplantation and Cellular Therapy and Blood Cancer Journal.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Yi Lin

Impact in

Papers in i

In The Last Decade

Yi Lin

Yi Lin's Hit Papers

Peers

Countries citing papers authored by Yi Lin

Fields of papers citing papers by Yi Lin

All Works

About Yi Lin

Explore authors with similar magnitude of impact

Papers in